<DOC>
	<DOCNO>NCT02427958</DOCNO>
	<brief_summary>The purpose study ass long-term safety efficacy leuprorelin treatment Central Precocious Puberty ( CPP ) .</brief_summary>
	<brief_title>A Study Assess Safety Efficacy Leuprorelin Central Precocious Puberty Chinese Patients</brief_title>
	<detailed_description>The drug test study call leuprorelin . It administer 1 month subcutaneous depot . Leuprorelin test treat child CPP . This study look development internal external genital organ appearance secondary sexual characteristic pre-pubertal child take leuprorelin . The study enroll approximately 300 patient . Participants body weight &gt; =20 kg receive recommend dose leuprorelin 3.75 mg subcutaneous injection every 4 week 96 week . Participants body weight &lt; 20 kg receive recommend dose 1.88 mg subcutaneous injection every 4 week 96 week . This trial conduct China . The overall time participate study 104 week . Participants make 11 visit clinic , followed-up physician long-term basis stable puberty reach .</detailed_description>
	<mesh_term>Puberty , Precocious</mesh_term>
	<criteria>1 . In opinion investigator , subject and/or parent ( ) legal guardian capable understand comply protocol requirement . 2 . The subject subject 's parent ( ) legally acceptable representative sign date write , informed consent form require privacy authorization prior initiation study procedure . 3 . Has onset appearance secondary sexual characteristic earlier age 8.0 year girls earlier 9.0 year boys symptom persistent , confirm diagnosis CPP . 4 . Has basal luteinizing hormone ( LH ) level great ( &gt; ) 5.0 international unit per liter ( IU/L ) peak LH &gt; 3.3 IU/L LH/folliclestimulating factor ( FSH ) &gt; 0.6 stimulation test . 5 . Has evidence gonadal development evaluate ultrasonography : ovarian volume &gt; =1 milliliter ( mL ) multiple follicle &gt; =4 millimeter ( mm ) ovary uterine enlargement female testicular volume &gt; =4 mL male . 6 . Has advance bone age ( BA ) &gt; =1 year BA le equal ( &lt; = ) 11.5 year females &lt; =12.5 year males OR predict adult height &lt; 150 centimeter ( cm ) females &lt; 160 cm male OR standard deviation score ( SDS ) &lt; 2 standard deviation ( SD ) OR rapid growth define growth BA /growth chronologic age &gt; 1 . BA determine Greulich Pyle standard TannerWhitehouse 3 ( TW3 ) standard screen . 7 . Has anticipate treatment duration least 2 year investigator 's judgment . 8 . A male subject nonsterilized sexually active female partner childbearing potential agrees use adequate contraception signing inform consent throughout duration study 90 day last dose . 9 . A female subject childbearing potential sexually active nonsterilized male partner agree use routinely adequate contraception signing inform consent throughout duration study . 10 . The female subject , discretion investigator , deem child bear potential must provide negative urine pregnancy text Day 1 Day 1 prior drug administration . 1 . Has receive investigational compound within 30 day prior Screening . 2 . Has receive gonadotropinreleasing hormone analog ( GnRHa ) treatment previous clinical study therapeutic agent . 3 . Is immediate family member , study site employee , dependent relationship study site employee involve conduct study ( example [ eg ] , spouse , parent , child , sibling ) may consent duress . 4 . Has find his/her medical history , physical examination , safety clinical laboratory test give reasonable suspicion underlie disease might interfere conduct trial . 5 . Has concomitant medical condition , opinion investigator , may expose subject unacceptable level safety risk affect subject compliance . 6 . Has screen abnormal laboratory value suggest clinically significant underlying disease condition may prevent subject enter study ; subject : creatinine &gt; =1.5 milligram per deciliter ( mg/dL ) , alanine aminotransferase ( ALT ) and/or aspartate aminotransferase ( AST ) &gt; 2 time upper limit normal ( ULN ) , total bilirubin &gt; 2.0 mg/dL , AST/ALT elevate limit normal value . 7 . Has history clinical manifestation significant adrenal thyroid diseases intracranial tumor OR history malignant disease . 8 . Has history hypersensitivity allergy leuprorelin , related compound include excipients compound . 9 . Has diagnosis peripheral precocious puberty . 10 . Has history drug abuse ( define illicit drug use ) history alcohol abuse within 1 year prior Screening Visit . 11 . Subject parent ( ) , discretion investigator , unlikely comply protocol unsuitable reason . 12 . If female , subject childbearing potential ( eg , sterilize ) . 13 . If female , subject pregnant lactating intend become pregnant , , within 1 month participate study ; intend donate ova time period . 14 . If male , subject intend donate sperm course study 90 day thereafter . 15 . Has participate another clinical study and/or receive investigational compound within 30 day prior Screening .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>9 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Drug Therapy</keyword>
</DOC>